ロード中...
Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer (NSCLC), is poorly differentiated and highly aggressive. Treatment is limited, and the prognosis is poor. Pembrolizumab is an anti-programmed death (PD)-1 antibody with good efficacy in NSCLC. Recent stud...
保存先:
| 出版年: | World J Clin Cases |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Baishideng Publishing Group Inc
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7360715/ https://ncbi.nlm.nih.gov/pubmed/32742998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i13.2876 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|